Atlas Trials

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

Clinical trial NCT02962401 · COMPLETED

Trial details

NCT number
NCT02962401
Sponsor
French Innovative Leukemia Organisation
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Waldenstrom Macroglobulinemia
Start date
2017-03-07
Primary completion
2020-08-31
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.